Update on the use of calcium antagonists on hypertension

被引:0
作者
R Hernández-Hernández
M Velasco
M J Armas-Hernández
M C Armas-Padilla
机构
[1] Clinical Pharmacology Unit,
[2] School of Medicine,undefined
[3] Universidad Centroccidental Lisandro Alvarado,undefined
[4] Clinical Pharmacology Unit,undefined
[5] Vargas School of Medicine,undefined
[6] Central University of Venezuela,undefined
来源
Journal of Human Hypertension | 2002年 / 16卷
关键词
calcium antagonists; dihydropyridines;
D O I
暂无
中图分类号
学科分类号
摘要
Calcium antagonists represent an important group of drugs for the treatment of hypertension; they are effective in the whole range of severity of the disease. Dihy- dropyridine derivatives are most frequently used, and can be used in association with other antihypertensive drugs; meanwhile phenylalkylamines and benzothiazepines are contraindicated in association with beta-blocker drugs. Calcium antagonists with slow starting effect and long duration of action are the choice for use in long-term antihypertensive treatment. This group of drugs is specially indicated in elderly patients, in those with diabetes mellitus and in patients with coronary heart disease. Phenylalkylamines and benzothiazepine derivatives are also used in patients with supraventricular arrhythmias. This group of agents is as safe as diuretics, angiotensin-converting enzyme-inhibitors and beta-blocking drugs in the long-term treatment of hypertension.
引用
收藏
页码:S114 / S117
相关论文
共 46 条
  • [1] Fleckenstein A(1983)History of calcium antagonists Circ Res Suppl 11 1-16
  • [2] Singh BN(1986)The mechanism of action of calcium antagonist relative to their clinical application Br J Clin Pharmacol 21 (Suppl 2) 109-122
  • [3] Hernández-Hernández R(1994)Farmacología Clínica de los calcio antagonistas en la hipertensión arterial Boletín Médico de Postgrado 10 127-138
  • [4] Donnelly R(1988)Nifedipine: individual responses and concentration-effect relationship Hypertension 12 443-449
  • [5] Cubeddu LX(1986)Comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response JAMA 256 2214-2221
  • [6] Brown MJ(2000)Morbidity and mortality inpatients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in the Hypertension Treatment (INSIGHT) Lancet 356 366-372
  • [7] Bond MG(1995)Potential modification of plaque behavior through the European lacidipine study on atherosclerosis J Cardiovasc Pharmacol 25 (Suppl 3) S11-S16
  • [8] Mercuri M(1986)Role of calcium channel blockers in the treatment of hypertension Am Heart J 111 363-382
  • [9] Halperin A(2000)Current status of safety and efficacy of calcium channel blockers in cardiovascular disease: a critical analysis based on 100 studies Prog Cardiovasc Dis 43 171-196
  • [10] Cubeddu LX(1995)The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 274 620-625